The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Cantor Fitzgerald on December 12, 2024. The analyst firm set a price target for $90.00 expecting BMRN to rise to within 12 months (a possible 37.07% upside). 54 analyst firms have reported ratings in the last year.

The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Cantor Fitzgerald, and Biomarin Pharmaceutical reiterated their overweight rating.

The last upgrade for Biomarin Pharmaceutical Inc happened on August 20, 2024 when Bernstein raised their price target to $110. Bernstein previously had a market perform for Biomarin Pharmaceutical Inc.

The last downgrade for Biomarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a reiterated with a price target of $90.00 to $90.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $65.66, which is out of the analyst’s predicted range.